How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
CCO Oncology Podcast
English - July 16, 2021 21:00 - 12 minutes - 11.8 MBCourses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.
Presenter:
Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs
Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs